DOCSLIB.ORG

(HGF/SF) on Fibroblast Growth Factor-2 (FGF-2) Levels in External Auditory Canal Cholesteatoma (EACC) Cell Culture

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(HGF/SF) on Fibroblast Growth Factor-2 (FGF-2) Levels in External Auditory Canal Cholesteatoma (EACC) Cell Culture in vivo 19: 599-604 (2005) Influence of Hepatocyte Growth Factor/Scatter Factor (HGF/SF) on Fibroblast Growth Factor-2 (FGF-2) Levels in External Auditory Canal Cholesteatoma (EACC) Cell Culture RAMIN NAIM1, RAY C. CHANG2, HANEEN SADICK1 and KARL HORMANN1 1Department of Otolaryngology, Head and Neck Surgery, University Hospital Mannheim, D-68135 Mannheim, Germany; 2Department of Otolaryngology, University of Miami/Jackson Memorial Hospital, Miami, Florida, U.S.A. Abstract. Background: In previous studies, we cited angiogenesis have been identified, including fibroblast circulatory disorders and hypoxia as etiological factors for the growth factor-a (aFGF), transforming growth factor-alpha formation of external auditory canal cholesteatoma (EACC) (TGF-alpha), TGF-beta, hepatocyte growth factor/scatter resulting in angiogenesis. Here, we investigate how the factor (HGF/SF), tumor necrosis factor-alpha (TNF-alpha), angiogenic factor hepatocyte growth factor/scatter factor angiogenin and interleukin-8 (IL-8) (3, 4). (HGF/SF) influences the level of another angiogenic factor Fibroblast growth factors (FGFs) are also considered FGF-2. Materials and Methods: After 16 to 72 hours of angiogenic factors, yet the exact relationship between FGF incubation with 20ng/ml HGF/SF, levels of VEGF in the and vascular development in normal and pathological tissue HGF/SF-treated and untreated culture was analyzed. We also has long remained elusive (5). FGF-2 is a member of the investigated the influence of HGF/SF (20-80ng/ml) on the FGF family, that comprises about nine members. FGF-2 concentration of FGF-2. Results: After 16 hours of incubation stimulates smooth muscle cell growth, wound healing, tissue with HGF/SF at 20ng/ml, FGF-2 was measured at 44.19pg/ml repair, and is increased in chronic inflammation (5). FGF-2 (control: 42.24pg/ml). After 72 hours, FGF-2 was at regulates the expression of several molecules including 23.41pg/ml (control: 14.83pg/ml). After 24 hours, 40ng/ml interstitial collagenase, urokinase type plasminogen HGF/SF showed the highest concentration of FGF-2. activator (uPA), plasminogen activator inhibitor (PAI-1), Conclusion: FGF-2 levels were initially elevated after treatment uPA receptor and integrins (6). For a long time, FGF-2 was with HGF/SF, however, further incubation did not show any considered as the angiogenesis factor. This was challenged increase. We assume that HGF/SF released FGF-2 in the by the discovery of several other angiogenic factors, such as matrix but did not induce FGF-2 expression. The most the vascular endothelial growth factor (VEGF), HGF/SF effective HGF/SF concentration was 40ng/ml. and its receptor c-Met (7). HGF/SF was initially discovered as a protein secreted by Angiogenesis, the formation of new blood vessels within fibroblasts resulting in epithelial/cell mitogenesis, tissue, has been an exciting and promising new area of proliferation, morphogenesis and motogenesis (8, 9). research. During angiogenesis, endothelial cell growth, HGF/SF is a 100 kDa pleiotropic mitogenic growth factor migration and vascular tube formation are regulated by pro- and its role in establishing angiogenesis, organ regeneration, and anti-angiogenic factors, matrix-degrading proteases and development of the nervous system and tumor invasion cell–extracellular matrix interactions (1). Matrix-bound emphasizes its important role in physiological and growth factors released by proteases and/or by angiogenic pathological processes (10). HGF/SF transduces signals via factors promote different diseases by enhancing endothelial its receptor, c-Met, a transmembrane tyrosine kinase proto- migration and growth (2). Several potential regulators of oncogene (11). In the field of otolaryngology, the external auditory canal cholesteatoma (EACC) is a very rare pathological entity (12). EACC is usually found in the inferior or posterior part of the Correspondence to: Dr. med. Ramin Naim, Univ.-HNO-Klinik, bony external ear canal, and it is characterized by permanent Theodor-Kutzer-Ufer, 68135 Mannheim, Germany. Tel: +49 621 growth of the epithelial tissue (13). Establishing the 383 1600, Fax: +49 621 383 1972, e-mail: [email protected] heidelberg.de cholesteatoma, the epithelial layer is the so-called matrix, and the adjacent subepithelial tissue is called perimatrix. The Key Words: External auditory canal cholesteatoma, FGF-2, matrix contains hyperplastic epithelial tissue, which HGF/SF, culture, keratinocyte. destructively tends to grow into adjacent anatomical structures 0258-851X/2005 $2.00+.40 599 in vivo 19: 599-604 (2005) such as the bony canal and mastoid cells, in contrast to immunoassay technique. A monoclonal antibody specific for FGF-2 keratosis obturans (14). The treatment of choice remains total was pre-coated onto a microplate. Standards and samples were surgical removal of the chronic inflammatory tissue (15). In pipetted into wells and FGF-2 present was bound by the immobilized antibody. After washing away unbound substances, an previous immunohistochemical studies, we showed that the enzyme-linked polyclonal antibody specific for FGF-2 was added growth factors VEGF, FGF-2, HGF/FS and the receptor to the wells. Following a wash to remove unbound antibody- c-Met are up-regulated in EACC (16). Sudhoff et al. reported enzyme reagent, a substrate solution was added to the wells and that angiogenesis is a pivotal factor for the formation of middle color developed in proportion to the amount of FGF-2 bound in ear cholesteatoma (17). They showed an altered expression the initial step. The color development was stopped and the and distribution of VEGF, FGF-2, TGF-· and TGF-‚1 in intensity of the color measured. middle ear cholesteatoma in relation to middle ear mucosa and The cells were grown in 96-well plates (Part 890218) with 12 strips of 8 walls coated with a mouse monoclonal antibody against auditory meatal skin. Further, Adamczyk et al. showed, by FGF-2. After 16, 24, 48 and 72 hours of incubation with 20 ng/ml immunohistochemistry, that EACC has enhanced expression HGF/SF, the expression of the FGF-2 protein in the supernants of of TGF-·, another potent angiogenic factor (18). the HGF/SF-treated and untreated culture cell lines was analyzed. Many authors reported that growth of several tumors is Concurrently, cultured EACC were incubated with different levels induced by HGF/SF, c-Met, VEGF and FGF-2 (5, 10, 11). of HGF/SF (20-80 ng/ml) for 24 hours. The assay recognized all The aim of this study was to explore the effect of HGF/SF different forms of FGF-2 (Figure 1a). on the matrix tissue of EACC with respect to the Western blot analysis. For Western blot analysis, the protein extracts concentration of FGF-2. To the best of our knowledge, we of the cholesteatoma cell culture were separated in a Tris-glycine are the first to grow EACC in vitro by removing gel (Invitrogen, Carlsbad, CA, USA) and transferred onto a mesenchymal tissue including fibroblasts from purified polyvinylidene difluoride membrane. Western blot analysis was endothelial cell culture (19). We present data that HGF/SF performed, as described by Zhang (20). influences the FGF-2 concentration, which might be important in the pathogenesis of EACC. Statistical analysis. The statistical analysis was calculated according to Bortz et al. (21). This method enabled the calculation of the p-value (p<0.05) for our small collective and data. Materials and Methods Results Tissue collection, isolation and culture of human skin keratinocytes and cholesteatoma culture. All EACC cell cultures were used at passage 3. Incubation up to 72 hours with 20 ng HGF/SF. After 16 hours All cells were obtained from 5 patients undergoing reconstructive of incubation with HGF/SF, FGF-2 was measured at 44.19 ear canal surgery at the Department of Otorhinolaryngology of the University of Mannheim, Germany. (Prior to surgery, written pg/ml. In untreated EACC (control), the level of FGF-2 was consent was obtained from all patients to take tissue samples of the 42.24 pg/ml. After 24 hours, the treated EACC culture resected cholesteatoma. This study was approved by the Ethics showed 46.36 pg/ml, while the control was 36.52 pg/ml. committee of the Faculty of Clinical Medicine, Mannheim, After 48 hours, the difference between the treated EACC University of Heidelberg, Germany). After removal of connective and control was less than 13% (24.79 pg/ml and 28.42 pg/ml, tissue, skin and cholesteatoma samples were cut into small pieces respectively). Cells incubated for 72 hours with HGF/SF had and incubated in a trypsin solution (0.25% trypsin in phosphate- 23.41 pg/ml FGF-2, whereas in untreated EACC culture buffered saline, PBS) overnight at 4ÆC. For primary culture of keratinocytes and cholesteatoma cells, the suspension of epidermal 14.83 pg/ml was measured. The proliferation assay, based cells was added onto mitomycin-treated (23.9 ÌM) human fibroblast on determination of total protein (Bradford), showed a slow monolayers and cultured in FAD2-medium (Dulbecco’s Modified growth of the EACC culture (311 Ìg/ml to 414 Ìg/ml). Eagle Medium and Ham’s F12 in a 3:1 ratio supplemented with fetal Comparing total protein content and the fraction of FGF-2 calf serum, adenine, insulin, triiodothyronin hydrocortisone, at different intervals of time, the concentration of FGF-2 epidermal growth factor, cholera toxin and penicillin/streptomycin decreased in untreated EACC; however, HGF/SF-incubated at 37ÆC in a 10% CO atmosphere). On reaching subconfluency, the 2 EACC culture showed an increase of FGF-2 protein feeder layer was removed by incubation with 0.02% ethylenediamine tetraacetic acid (EDTA) in PBS for 4 min at 37ÆC and the concentration as a fraction of total protein content. There cholesteatoma cells were further cultured in keratinocyte growth was a decrease of FGF-2 after 48 hours, which stagnated up medium (KGM, Clonetics, San Diego, CA, USA) without serum.
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Supplementary Table 1
    Supplementary table 1 List of the 92 proteins analyzed in the multiplex proximity extension assay (PEA) Long name (short name) UniProt No. LOD (pg/mL) Adenosine Deaminase (ADA) P00813 0.48 Artemin (ARTN) Q5T4W7 0.24 Axin-1 (AXIN1) O15169 61,0 Beta-nerve growth factor (Beta-NGF) P01138 0.48 Brain-derived neutrophic factor (BDNF) P23560 Caspase 8 (CASP-8) Q14790 0.48 C-C motif chemokine 4 (CCL4) P13236 1.9 C-C motif chemokine 19 (CCL19) Q99731 15,0 C-C motif chemokine 20 (CCL20) P78556 7.6 C-C motif chemokine 23 (CCL23) P55773 31,0 C-C motif chemokine 25 (CCL25) O15444 3.8 C-C motif chemokine 28 (CCL28) Q9NRJ3 61,0 CD40L receptor (CD40) P25942 0.01 CUB domain-containing protein 1 (CDCP1) Q9H5V8 0.12 C-X-C motif chemokine 1 (CXCL1) P09341 3.8 C-X-C motif chemokine 5 (CXCL5) P42830 0.95 C-X-C motif chemokine 6 (CXCL6) P80162 7.6 C-X-C motif chemokine 9 (CXCL9) Q07325 0.95 C-X-C motif chemokine 10 (CXCL10) P02778 7.6 C-X-C motif chemokine 11 (CXCL11) O14625 7.6 Cystatin D (CST5) P28325 1.9 Delta and Notch-like epidermal growth factor related receptor (DNER) Q8NFT8 0.95 Eotaxin-1 (CCL11) P51671 3.8 Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) Q13541 Fibroblast growth factor 5 (FGF-5) Q8NF90 1.9 Fibroblast growth factor 19 (FGF-19) O95750 7.6 Fibroblast growth factor 21 (FGF-21) Q9NSA1 31,0 Fibroblast growth factor 23 (FGF-23) Q9GZV9 122,0 Fms-related tyrosine kinase 3 ligand (FIt3L) P49771 0.01 Fractalkine (CX3CL1) P78423 15.3 Glial cell line-derived neutrophic factor (hGDNF) P39905 0.01 Hepatocyte growth factor (HGF)
    [Show full text]
  • Artificial Liver Support Potential to Retard Regeneration?
    REVIEW ARTICLE Artificial Liver Support Potential to Retard Regeneration? Emma J. Mullin, MBChB; Matthew S. Metcalfe, FRCS; Guy J. Maddern, MD Hypothesis: The concept of an “artificial liver” has been growth-promoting factors from these cultured hepato- in development for over 40 years. Such devices aim to cytes? temporarily assume metabolic and excretory functions of the liver, with removal of potentially hepatotoxic sub- Data Sources, Extraction, and Study Selection: stances, thereby clinically stabilizing patients and pre- Data were obtained using PubMed search for reports in- venting deterioration while awaiting transplantation. If volving liver support, extracorporeal circuits, dialysis, sufficient numbers of viable hepatocytes remain, regen- growth factors, and cytokines. Those reports specifi- eration and subsequent recovery of innate liver func- cally looking at the effect of artificial liver support on cy- tion may occur. However, these devices have not yet be- tokines and growth factors are discussed. come part of routine clinical use. Much less is known regarding the effect such devices have, if any, on circu- Conclusions: There is a paucity of information on the lating cytokines and growth factors and the subsequent key events and substances involved in hepatic regenera- effects on the regenerating liver. If these devices remove tion. In addition, there is a potential impact of liver sup- or reduce factors known to promote regeneration, is the port devices on the regeneration of substances associ- rate of regeneration retarded? Conversely, does the in- ated with hepatic regeneration. Further study is needed. corporation of hepatocytes into bioartificial support sys- tems confer an advantage through the production of Arch Surg.
    [Show full text]
  • Human TGF Alpha ELISA Kit Basic Information: Catalog No.: UE1330 Size: 96T for Research Use Only
    Efficient Professional Protein and Antibody Platforms Human TGF alpha ELISA Kit Basic information: Catalog No.: UE1330 Size: 96T For research use only. Not for diagnostic or therapeutic procedures. I. INTRODUCTION Transforming growth factor alpha (TGF-α) is upregulated in some human cancers. It is produced in macrophages, brain cells, and keratinocytes, and induces epithelial development. It is closely related to EGF, and can also bind to the EGF receptor with similar effects . TGFα stimulates neural cell proliferation in the adult injured brain. Transforming growth factor alpha gene (TGFA) maps to human chromosome 2 close to the breakpoint of the t (2;8) variant translocation in Burkitt lymphoma. Synthetic TGF-alpha was as active as murine epidermal growth factor in binding to the epidermal growth factor receptor and in stimulation of anchorage-dependent and of anchorage-independent growth of normal indicator cells in culture. Synthetic TGF-alpha stimulated plasminogen activator production in A 431 and HeLa cells; the stimulation was similar to that induced by epidermal growth factor. Furthermore, synthetic human TGF-alpha showed similar immunoreactivity when compared with rat TGF-alpha. Thus, the 50-amino acid TGF-alpha is likely to be the bioactive principle produced and secreted by tumor cell lines. II. ASSAY PRINCIPLES The Gene Universal Human TGF alpha ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human TGF alpha in Cell Culture Supernatants, Serum, Plasma. This assay employs an antibody specific for Human TGF alpha coated on a 96-well plate. Standards and samples are pipetted into the wells and TGF alpha present in a sample is bound to the wells by the immobilized antibody.
    [Show full text]
  • Proseek Multiplex Oncology I V296×96
    Proseek Multiplex Oncology I v296×96 Adrenomedullin (AM) P35318 Fms-related tyrosine kinase 3 ligand (Flt3L) P49771 Amphiregulin (AR) P15514 Folate receptor alpha (FR-alpha) P15328 Angiopoietin-1 receptor (TIE2) Q02763 Follistatin (FS) P19883 B-cell activating factor (BAFF) Q9Y275 Furin (FUR) P09958 Cadherin-3 (CDH3) P22223 Growth hormone (GH) P01241 Carbonic anhydrase IX (CAIX) Q16790 Growth/differentiation factor 15 (GDF-15) Q99988 Carcinoembryonic antigen (CEA) P06731 Heparin-binding EGF-like growth factor (HB-EGF) Q99075 Caspase-3 (CASP-3) P42574 Hepatocyte growth factor (HGF) P14210 C-C motif chemokine 19 (CCL19) Q99731 ICOS ligand (ICOSLG) O75144 CD40 ligand (CD40-L) P29965 Immunoglobulin-like transcript 3 (ILT-3) Q8NHJ6 C-X-C motif chemokine 5 (CXCL5 ) P42830 Integrin alpha-1 (ITGA1) P56199 C-X-C motif chemokine 9 (CXCL9 ) Q07325 Interferon gamma (IFN-gamma) P01579 C-X-C motif chemokine 10 (CXCL10 ) P02778 Interleukin-1 receptor antagonist protein (IL-1ra) P18510 C-X-C motif chemokine 11 (CXCL11 ) O14625 Interleukin-2 (IL-2) P60568 C-X-C motif chemokine 13 (CXCL13 ) O43927 Interleukin-6 (IL-6) P05231 Cyclin-dependent kinase inhibitor 1 (CDKN1A) P38936 Interleukin-6 receptor subunit alpha (IL-6RA) P08887 Cystatin-B (CSTB) P04080 Interleukin-7 (IL-7) P13232 Early activation antigen CD69 (CD69 ) Q07108 Interleukin-8 (IL-8) P10145 Epidermal growth factor receptor (EGFR ) P00533 Interleukin-12 (IL-12) P29460; P29459 Epididymal secretory protein E4 (HE4 ) Q14508 Interleukin-17 receptor B (IL-17RB ) Q9NRM6 Epithelial cell adhesion molecule
    [Show full text]
  • The Roles of Fgfs in the Early Development of Vertebrate Limbs
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW The roles of FGFs in the early development of vertebrate limbs Gail R. Martin1 Department of Anatomy and Program in Developmental Biology, School of Medicine, University of California at San Francisco, San Francisco, California 94143–0452 USA ‘‘Fibroblast growth factor’’ (FGF) was first identified 25 tion of two closely related proteins—acidic FGF and ba- years ago as a mitogenic activity in pituitary extracts sic FGF (now designated FGF1 and FGF2, respectively). (Armelin 1973; Gospodarowicz 1974). This modest ob- With the advent of gene isolation techniques it became servation subsequently led to the identification of a large apparent that the Fgf1 and Fgf2 genes are members of a family of proteins that affect cell proliferation, differen- large family, now known to be comprised of at least 17 tiation, survival, and motility (for review, see Basilico genes, Fgf1–Fgf17, in mammals (see Coulier et al. 1997; and Moscatelli 1992; Baird 1994). Recently, evidence has McWhirter et al. 1997; Hoshikawa et al. 1998; Miyake been accumulating that specific members of the FGF 1998). At least five of these genes are expressed in the family function as key intercellular signaling molecules developing limb (see Table 1). The proteins encoded by in embryogenesis (for review, see Goldfarb 1996). Indeed, the 17 different FGF genes range from 155 to 268 amino it may be no exaggeration to say that, in conjunction acid residues in length, and each contains a conserved with the members of a small number of other signaling ‘‘core’’ sequence of ∼120 amino acids that confers a com- molecule families [including WNT (Parr and McMahon mon tertiary structure and the ability to bind heparin or 1994), Hedgehog (HH) (Hammerschmidt et al.
    [Show full text]
  • Canine TGF-Alpha ELISA Kit
    Canine TGF-alpha ELISA Kit Catalog #: AYQ-E10339 (96 wells) User Manual This kit is designed to quantitatively detect the levels of Canine TGF-alpha in cell lysates, serum/ plasma and other suitable sample solution. Manufactured and Distributed by: AssaySolution 310 W Cummings Park, Woburn, MA, 01801, USA Phone: (617) 238-1396, Fax: (617) 380-0053 Email: [email protected] FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES Important notes Before using this product, please read this manual carefully; after reading the subsequent contents of this manual, please note the following specially: • The operation should be carried out in strict accordance with the provided instructions. • Store the unused strips in a sealed foil bag at 2-8°C. • Always avoid foaming when mixing or reconstituting protein solutions. • Pipette reagents and samples into the center of each well, avoid bubbles. • The samples should be transferred into the assay wells within 15 minutes of dilution. • We recommend that all standards, testing samples are tested in duplicate. • Using serial diluted sample is recommended for first test to get the best dilution factor. • If the blue color develops too light after 15 minutes incubation with the substrate, it may be appropriate to extend the incubation time (Do not over-develop). • Avoid cross-contamination by changing tips, using separate reservoirs for each reagent. • Avoid using the suction head without extensive wash. • Do not mix the reagents from different batches. • Stop Solution should be added in the same order of the Substrate Solution. • TMB developing agent is light-sensitive. Avoid prolonged exposure to the light.
    [Show full text]
  • Adrenomedullin Antagonist Suppresses Tumor Formation in Renal
    1379-1386.qxd 16/4/2010 10:31 Ì ™ÂÏ›‰·1379 INTERNATIONAL JOURNAL OF ONCOLOGY 36: 1379-1386, 2010 Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization KUNIHIKO TSUCHIYA1,2,3,4*, KYOKO HIDA2*, YASUHIRO HIDA5, CHIKARA MURAKI2,3, NORITAKA OHGA2,3, TOMOSHIGE AKINO2,3,4, TAKESHI KONDO4, TETSUYA MISEKI1, KOJI NAKAGAWA1, MASANOBU SHINDOH3, TORU HARABAYASHI4, NOBUO SHINOHARA4, KATSUYA NONOMURA4 and MASANOBU KOBAYASHI1,7 1Division of Cancer Biology, Institute for Genetic Medicine, Hokkaido University; 2Division of Vascular Biology, 3Division of Oral Pathobiology, Hokkaido University, Graduate School of Dental Medicine; 4Department of Urology, 5Department of Surgical Oncology, 6Department of Gastroenterology and Hematology, Hokkaido University, Graduate School of Medicine; 7School of Nursing & Social Services, Health Sciences University of Hokkaido, Sapporo, Japan Received November 26, 2009; Accepted January 25, 2010 DOI: 10.3892/ijo_00000622 Abstract. Adrenomedullin (AM) is a multifunctional 52-amino (EPC) into circulation was inhibited by AMA. These results acid peptide. AM has several effects and acts as a growth suggest that AMA can be considered a good anti-angiogenic factor in several types of cancer cells. Our previous study reagent that selectively targets TECs and EPC in renal revealed that an AM antagonist (AMA) suppressed the cancer. growth of pancreatic tumors in mice, although its mechanism was not elucidated. In this study, we constructed an AMA Introduction expression vector and used it to treat renal cell carcinoma (RCC) in mice. This AMA expression vector significantly Renal cell carcinoma (RCC) is a refractory cancer, and cyto- reduced tumor growth in mice.
    [Show full text]
  • Review Peptide Gene Expression in Gastrointestinal Mucosal
    286 Gut 2000;46:286–292 Review Gut: first published as 10.1136/gut.46.2.286 on 1 February 2000. Downloaded from Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy? Summary repair by stimulating the migration of surviving cells from Many genes, some encoding peptides, are upregulated after the edge of the damaged region over the denuded area, a mucosal damage in the gastrointestinal mucosa: we have process known as epithelial restitution. Exogenous looked for an ordered sequence in the expression of genes TFF2/SP increases cell migration in in vitro models of cell such as c-fos,c-jun, egr-1, Sp-1, epidermal growth factor, wounding34and also acts as a cytoprotective agent in rats transforming growth factors á and â, trefoil peptides, epi- treated with indomethacin. Thus TFF2/SP has been dermal growth factor receptor, hepatocyte growth factor, proposed as a rapid response peptide.5 c-met, fibroblast growth factor, platelet derived growth fac- Epidermal growth factor (EGF) is an 53 amino acid tor, and vascular endothelial growth factor. All of these peptide found in the salivary glands and the duodenal gene products play an important reparative role, assisting Brunner’s glands. It is one of the most extensively studied appropriate healing of the damaged mucosa. There does peptides in healing of gastric mucosal lesions,6–9 but its indeed seem to be a temporal sequence in this gene exact function in human physiology is not yet fully defined. expression, but there is a certain degree of redundancy EGF is a potent stimulant of growth and repair when within the system, both in terms of receptor binding and infused systemically, inhibits gastric acid secretion, and has the function of the gene products.
    [Show full text]
  • Table S1. List of All Proteins Included in the Proseek® Multiplex Oncology I V2 96X96 Cancer Panel
    Table S1. List of all proteins included in the Proseek® Multiplex Oncology I v2 96x96 Cancer Panel. Adrenomedullin (AM) Ezrin (EZR) Latency-associated peptide transforming growth factor beta-1 (LAP TGF-beta-1) Amphiregulin (AR) Fas antigen ligand (FasL) Angiopoietin-1 receptor (TIE2) FAS-associated death domain protein (FADD) Lipopolysaccharide-induced tumor necrosis factor- alpha factor (LITAF) B-cell activating factor (BAFF) Fms-related tyrosine kinase 3 ligand (Flt3L) Cadherin-3 (CDH3) Folate receptor alpha (FR-alpha) Macrophage colony-stimulating factor 1 (CSF-1) Carbonic anhydrase IX (CAIX) Follistatin (FS) Matrix metalloproteinase-1 (MMP-1) Carcinoembryonic antigen (CEA) Furin (FUR) Melanoma-derived growth regulatory protein (MIA) Caspase-3 (CASP-3) Growth hormone (GH) MHC class I polypeptide-related sequence A (MIC-A) C-C motif chemokine 19 (CCL19) Growth/differentiation factor 15 (GDF-15) Midkine (MK) CD40 ligand (CD40-L) Heparin-binding EGF-like growth factor (HB-EGF) Monocyte chemotactic protein 1 (MCP-1) C-X-C motif chemokine 5 (CXCL5) Hepatocyte growth factor (HGF) Myeloid differentiation primary response protein MyD88 (MYD88) C-X-C motif chemokine 9 (CXCL9) ICOS ligand (ICOSLG) C-X-C motif chemokine 10 (CXCL10) Immunoglobulin-like transcript 3 (ILT-3) NF-kappa-B essential modulator (NEMO) C-X-C motif chemokine 11 (CXCL11) Integrin alpha-1 (ITGA1) NT-3 growth factor receptor (NTRK3) C-X-C motif chemokine 13 (CXCL13) Interferon gamma (IFN-gamma) Ovarian cancer-related tumor marker CA 125 (CA-125) Cyclin-dependent kinase inhibitor
    [Show full text]
  • Promoting Effect of Basic Fibroblast Growth Factor in Synovial Mesenchymal Stem Cell-Based Cartilage Regeneration
    International Journal of Molecular Sciences Article Promoting Effect of Basic Fibroblast Growth Factor in Synovial Mesenchymal Stem Cell-Based Cartilage Regeneration Gensuke Okamura 1, Kosuke Ebina 2,* , Makoto Hirao 3, Ryota Chijimatsu 4, Yasukazu Yonetani 5, Yuki Etani 3, Akira Miyama 3, Kenji Takami 3, Atsushi Goshima 3, Hideki Yoshikawa 6, Takuya Ishimoto 7, Takayoshi Nakano 7 , Masayuki Hamada 5, Takashi Kanamoto 8 and Ken Nakata 8 1 Department of Orthopaedic Surgery, Osaka Rosai Hospital, 1179-3, Nagasonecho, Kita-ku, Sakai, Osaka 591-8025, Japan; [email protected] 2 Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan 3 Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; [email protected] (M.H.); [email protected] (Y.E.); [email protected] (A.M.); [email protected] (K.T.); [email protected] (A.G.) 4 Sensory and Motor System Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; [email protected] 5 Department of Orthopaedic Surgery, Hoshigaoka Medical Center, Japan Community Health Care Organization, 4-8-1 Hoshigaoka, Hirakata, Osaka 573-8511, Japan; [email protected] (Y.Y.); [email protected] (M.H.) 6 Department of Orthopaedic Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibaharacho, Toyonaka, Osaka 560-8565, Japan; [email protected] 7 Division of Materials and Manufacturing
    [Show full text]
  • TGF-Α Antisense Gene Therapy Inhibits Head and Neck Squamous Cell
    Gene Therapy (2000) 7, 1906–1914 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00 www.nature.com/gt ACQUIRED DISEASES RESEARCH ARTICLE TGF-␣ antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo S Endo1, Q Zeng1, NA Burke2,YHe3, MF Melhem4, SF Watkins2, MN Lango1, SD Drenning1, L Huang3 and J Rubin Grandis1,2 Departments of 1Otolaryngology, 2Cell Biology and Physiology, 3Pharmacology, 4Pathology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA Unlike normal mucosal squamous epithelial cells, head and remained localized to the nucleus for up to 3 days. Direct neck squamous cell carcinomas (HNSCCs) overexpress inoculation of the TGF-␣ antisense (but not the correspond- TGF-␣ mRNA and protein which is required to sustain the ing sense) construct into established HNSCC tumors proliferation of HNSCC cells in vitro. To determine whether resulted in inhibition of tumor growth. Sustained antitumor TGF-␣ expression contributes to tumor growth in vivo, cat- effects were observed for up to 1 year after the treatments ionic liposome-mediated gene transfer was used to deliver were discontinued. Down-modulation of TGF-␣ was an antisense expression construct targeting the human TGF- accompanied by increased apoptosis in vivo. These experi- ␣ gene into human head and neck tumor cells, grown as ments indicate that interference with the TGF-␣/EGFR subcutaneous xenografts in nude mice. The TGF-␣ anti- autocrine signaling pathway may be an effective therapeutic sense gene was immediately detected in the cytoplasm of strategy for cancers which overexpress this ligand/receptor the tumor cells, translocated to the nucleus by 12 h and pair.
    [Show full text]